224 related articles for article (PubMed ID: 37441479)
1. Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome.
Kavanagh D; Greenbaum LA; Bagga A; Karki RG; Chen CW; Vasudevan S; Charney A; Dahlke M; Fakhouri F
Kidney Int Rep; 2023 Jul; 8(7):1332-1341. PubMed ID: 37441479
[TBL] [Abstract][Full Text] [Related]
2. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
[TBL] [Abstract][Full Text] [Related]
3. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
[TBL] [Abstract][Full Text] [Related]
4. Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial.
Bomback AS; Kavanagh D; Vivarelli M; Meier M; Wang Y; Webb NJA; Trapani AJ; Smith RJH
Kidney Int Rep; 2022 Oct; 7(10):2150-2159. PubMed ID: 36217526
[TBL] [Abstract][Full Text] [Related]
5. Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria.
Xu B; Kang B; Chen J; Li S; Zhou J
Blood Rev; 2024 Jul; 66():101210. PubMed ID: 38811284
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.
Rizk DV; Rovin BH; Zhang H; Kashihara N; Maes B; Trimarchi H; Perkovic V; Meier M; Kollins D; Papachristofi O; Charney A; Barratt J
Kidney Int Rep; 2023 May; 8(5):968-979. PubMed ID: 37180505
[TBL] [Abstract][Full Text] [Related]
7. Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
Peffault de Latour R; Röth A; Kulasekararaj AG; Han B; Scheinberg P; Maciejewski JP; Ueda Y; de Castro CM; Di Bona E; Fu R; Zhang L; Griffin M; Langemeijer SMC; Panse J; Schrezenmeier H; Barcellini W; Mauad VAQ; Schafhausen P; Tavitian S; Beggiato E; Chew LP; Gaya A; Huang WH; Jang JH; Kitawaki T; Kutlar A; Notaro R; Pullarkat V; Schubert J; Terriou L; Uchiyama M; Wong Lee Lee L; Yap ES; Sicre de Fontbrune F; Marano L; Alashkar F; Gandhi S; Trikha R; Yang C; Liu H; Kelly RJ; Höchsmann B; Kerloeguen C; Banerjee P; Levitch R; Kumar R; Wang Z; Thorburn C; Maitra S; Li S; Verles A; Dahlke M; Risitano AM
N Engl J Med; 2024 Mar; 390(11):994-1008. PubMed ID: 38477987
[TBL] [Abstract][Full Text] [Related]
8. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
Zhang H; Rizk DV; Perkovic V; Maes B; Kashihara N; Rovin B; Trimarchi H; Sprangers B; Meier M; Kollins D; Papachristofi O; Milojevic J; Junge G; Nidamarthy PK; Charney A; Barratt J
Kidney Int; 2024 Jan; 105(1):189-199. PubMed ID: 37914086
[TBL] [Abstract][Full Text] [Related]
9. Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study.
Jang JH; Wong L; Ko BS; Yoon SS; Li K; Baltcheva I; Nidamarthy PK; Chawla R; Junge G; Yap ES
Blood Adv; 2022 Aug; 6(15):4450-4460. PubMed ID: 35561315
[TBL] [Abstract][Full Text] [Related]
10. Iptacopan in Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study.
Vivarelli M; Bomback AS; Meier M; Wang Y; Webb NJA; Veldandi UK; Smith RJH; Kavanagh D
Kidney Int Rep; 2024 Jan; 9(1):64-72. PubMed ID: 38312795
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
[TBL] [Abstract][Full Text] [Related]
12. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults.
Barbour T; Scully M; Ariceta G; Cataland S; Garlo K; Heyne N; Luque Y; Menne J; Miyakawa Y; Yoon SS; Kavanagh D;
Kidney Int Rep; 2021 Jun; 6(6):1603-1613. PubMed ID: 34169200
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Ariceta G
Expert Rev Clin Pharmacol; 2023 May; 16(5):401-410. PubMed ID: 37128905
[TBL] [Abstract][Full Text] [Related]
15. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
[TBL] [Abstract][Full Text] [Related]
16. Complement activation in diseases presenting with thrombotic microangiopathy.
Meri S
Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
[TBL] [Abstract][Full Text] [Related]
17. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Ariceta G; Dixon BP; Kim SH; Kapur G; Mauch T; Ortiz S; Vallee M; Denker AE; Kang HG; Greenbaum LA;
Kidney Int; 2021 Jul; 100(1):225-237. PubMed ID: 33307104
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome.
Shen YM
Thromb J; 2016; 14(Suppl 1):19. PubMed ID: 27766045
[TBL] [Abstract][Full Text] [Related]
19. Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab.
Cammett TJ; Garlo K; Millman EE; Rice K; Toste CM; Faas SJ
Mol Diagn Ther; 2023 Jan; 27(1):61-74. PubMed ID: 36329366
[TBL] [Abstract][Full Text] [Related]
20. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
Krishnappa V; Gupta M; Elrifai M; Moftakhar B; Ensley MJ; Vachharajani TJ; Sethi SK; Raina R
Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
